Richard Finn, MD

Articles

EMERALD-1 Study Results

October 25th 2024

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Discussion and Summary

October 25th 2024

Panelists discuss the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.

LEAP-012 Study Results

October 25th 2024

Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.

Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

October 25th 2024

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Use of monotherapy (IO or TKI) or localized treatment in First Line

October 18th 2024

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

Current Treatment in First Line – IO + TKI or IO + IO

October 18th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Treatment Decisions Based on BLCL Stage

October 7th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

October 7th 2024

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

April 23rd 2024

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Locoregional Therapies for Intermediate-Stage HCC

April 23rd 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

HCC Staging: Improving Treatment Strategies

April 16th 2024

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

Examining the Role of Liver Function in HCC

April 16th 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts

July 27th 2022

Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.

Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

July 27th 2022

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents

July 20th 2022

Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.

Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy

July 20th 2022

Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.

Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC

July 13th 2022

Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.

HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors

July 13th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer

July 6th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors

July 6th 2022

Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.

NEXT PAGE
PREVIOUS PAGE